StreetInsider.com News Articles

BTIG Assumes Verastem (VSTM) at Buy

Wed, 11 Mar 2026 16:11:41 -0400

(Updated - March 11, 2026 4:11 PM EDT)

BTIG analyst Jeet Mukherjee assumes coverage on Verastem (NASDAQ: VSTM) with a Buy rating and a price target of $19.00.

The analyst comments "We see VSTM as an undervalued oncology story at an attractive entry point supported by two main pipeline programs. The strong launch of AVMAPKI FAKZYNJA in LGSOC continues to beat consensus, with potential for ~$1B in peak sales with conservative market penetration assumptions. Second is KRASG12D inhibitor VS-7375, where we expect additional data updates from the US ph 1/2 study of '7375 this year and next. We believe the next several

BTIG Assumes Verastem (VSTM) at Buy

Wed, 11 Mar 2026 16:11:41 -0400

(Updated - March 11, 2026 4:11 PM EDT)

BTIG analyst Jeet Mukherjee assumes coverage on Verastem (NASDAQ: VSTM) with a Buy rating and a price target of $19.00.

Verastem (VSTM) PT Lowered to $15 at Mizuho

Fri, 06 Mar 2026 06:59:43 -0400

Mizuho analyst Graig Suvannavejh lowered the price target on Verastem (NASDAQ: VSTM) to $15.00 (from $18.00) while maintaining a Outperform rating.

Jefferies Reiterates Buy Rating on Verastem (VSTM); "catalyst-rich 2026"

Thu, 05 Mar 2026 10:06:18 -0400

Jefferies analyst Clara Dong reiterated a Buy rating and $19.00 price target on Verastem (NASDAQ: VSTM)

The analyst commented, "Co reported 4Q25 CO-PACK net rev of ~$17.5M (vs JEF $17.6M & cons $16.5M) following May'25 approval, and Co expects the LGSOC launch to be selfsustaining by 2H26. The latest NCCN guidance remained limited to KRASm LGSOC, but it should not disrupt uptake, in our view. G12D continues to de‑risk on dose and safety: monotherapy has cleared 900 mg QD with no DLTs, while combination with cetuximab has cleared up to 600 mg QD, setting up a catalyst-rich 2026."

For an analyst ratings

Form 8-K Verastem, Inc. For: Mar 04

Wed, 04 Mar 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260304/26111353.html

Form 8-K Verastem, Inc. For: Mar 04

Wed, 04 Mar 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260304/26111353.html

Verastem Oncology (VSTM) Misses Q4 EPS by 50c

Wed, 04 Mar 2026 16:13:47 -0400

Verastem Oncology (NASDAQ: VSTM) reported Q4 EPS of ($0.50). Revenue for the quarter came in at $17.54 million.

For earnings history and earnings-related data on Verastem Oncology (VSTM) click here.

Form 10-K Verastem, Inc. For: Dec 31

Wed, 04 Mar 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260304/26111006.html

Form 10-K Verastem, Inc. For: Dec 31

Wed, 04 Mar 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260304/26111006.html

Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates

Wed, 04 Mar 2026 16:01:00 -0400

AVMAPKI™ FAKZYNJA™ CO-PACK net product revenues of $17.5 million for the fourth quarter of 2025 and $30.9 million for the full year 2025, following accelerated U.S. FDA approval in May 2025

Based on FDA guidance, Company to develop Phase 2 registration-directed protocols to evaluate VS-7375, a highly selective, oral KRAS G12D (ON/OFF) inhibitor with best-in-class potential, in 2L PDAC, 2L/3L NSCLC and 2L+ CRC in combination with cetuximab

Cleared multiple dose levels of VS-7375 with no DLTs, continuing dose escalation to 1200 mg QD; cleared 600 mg QD dose level of VS-7375 in combination with cetuximab with no DLTs;

Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates

Wed, 04 Mar 2026 16:01:00 -0400

AVMAPKI™ FAKZYNJA™ CO-PACK net product revenues of $17.5 million for the fourth quarter of 2025 and $30.9 million for the full year 2025, following accelerated U.S. FDA approval in May 2025
Based on FDA guidance, Company to develop Phase 2 registration-directed protocols to evaluate VS-7375, a highly selective, oral KRAS G12D (ON/OFF) inhibitor with best-in-class potential, in 2L PDAC, 2L/3L NSCLC and 2L+ CRC in combination with cetuximab
Cleared multiple dose levels of VS-7375 with no DLTs, continuing dose escalation to 1200 mg QD; cleared 600 mg QD dose level of VS-7375 in combination with cetuximab with no DLTs;

Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates

Wed, 04 Mar 2026 16:01:00 -0400

AVMAPKI™ FAKZYNJA™ CO-PACK net product revenues of $17.5 million for the fourth quarter of 2025 and $30.9 million for the full year 2025, following accelerated U.S. FDA approval in May 2025
Based on FDA guidance, Company to develop Phase 2 registration-directed protocols to evaluate VS-7375, a highly selective, oral KRAS G12D (ON/OFF) inhibitor with best-in-class potential, in 2L PDAC, 2L/3L NSCLC and 2L+ CRC in combination with cetuximab
Cleared multiple dose levels of VS-7375 with no DLTs, continuing dose escalation to 1200 mg QD; cleared 600 mg QD dose level of VS-7375 in combination with cetuximab with no DLTs;

Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates

Wed, 04 Mar 2026 16:01:00 -0400

AVMAPKI™ FAKZYNJA™ CO-PACK net product revenues of $17.5 million for the fourth quarter of 2025 and $30.9 million for the full year 2025, following accelerated U.S. FDA approval in May 2025
Based on FDA guidance, Company to develop Phase 2 registration-directed protocols to evaluate VS-7375, a highly selective, oral KRAS G12D (ON/OFF) inhibitor with best-in-class potential, in 2L PDAC, 2L/3L NSCLC and 2L+ CRC in combination with cetuximab
Cleared multiple dose levels of VS-7375 with no DLTs, continuing dose escalation to 1200 mg QD; cleared 600 mg QD dose level of VS-7375 in combination with cetuximab with no DLTs;

Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates

Wed, 04 Mar 2026 16:01:00 -0400

AVMAPKI™ FAKZYNJA™ CO-PACK net product revenues of $17.5 million for the fourth quarter of 2025 and $30.9 million for the full year 2025, following accelerated U.S. FDA approval in May 2025
Based on FDA guidance, Company to develop Phase 2 registration-directed protocols to evaluate VS-7375, a highly selective, oral KRAS G12D (ON/OFF) inhibitor with best-in-class potential, in 2L PDAC, 2L/3L NSCLC and 2L+ CRC in combination with cetuximab
Cleared multiple dose levels of VS-7375 with no DLTs, continuing dose escalation to 1200 mg QD; cleared 600 mg QD dose level of VS-7375 in combination with cetuximab with no DLTs;

Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates

Wed, 04 Mar 2026 16:01:00 -0400

AVMAPKI™ FAKZYNJA™ CO-PACK net product revenues of $17.5 million for the fourth quarter of 2025 and $30.9 million for the full year 2025, following accelerated U.S. FDA approval in May 2025
Based on FDA guidance, Company to develop Phase 2 registration-directed protocols to evaluate VS-7375, a highly selective, oral KRAS G12D (ON/OFF) inhibitor with best-in-class potential, in 2L PDAC, 2L/3L NSCLC and 2L+ CRC in combination with cetuximab
Cleared multiple dose levels of VS-7375 with no DLTs, continuing dose escalation to 1200 mg QD; cleared 600 mg QD dose level of VS-7375 in combination with cetuximab with no DLTs;

Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates

Wed, 04 Mar 2026 16:01:00 -0400

AVMAPKI™ FAKZYNJA™ CO-PACK net product revenues of $17.5 million for the fourth quarter of 2025 and $30.9 million for the full year 2025, following accelerated U.S. FDA approval in May 2025
Based on FDA guidance, Company to develop Phase 2 registration-directed protocols to evaluate VS-7375, a highly selective, oral KRAS G12D (ON/OFF) inhibitor with best-in-class potential, in 2L PDAC, 2L/3L NSCLC and 2L+ CRC in combination with cetuximab
Cleared multiple dose levels of VS-7375 with no DLTs, continuing dose escalation to 1200 mg QD; cleared 600 mg QD dose level of VS-7375 in combination with cetuximab with no DLTs;

Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates

Wed, 04 Mar 2026 16:01:00 -0400

AVMAPKI™ FAKZYNJA™ CO-PACK net product revenues of $17.5 million for the fourth quarter of 2025 and $30.9 million for the full year 2025, following accelerated U.S. FDA approval in May 2025
Based on FDA guidance, Company to develop Phase 2 registration-directed protocols to evaluate VS-7375, a highly selective, oral KRAS G12D (ON/OFF) inhibitor with best-in-class potential, in 2L PDAC, 2L/3L NSCLC and 2L+ CRC in combination with cetuximab
Cleared multiple dose levels of VS-7375 with no DLTs, continuing dose escalation to 1200 mg QD; cleared 600 mg QD dose level of VS-7375 in combination with cetuximab with no DLTs;

Verastem (VSTM) PT Raised to $18 at Mizuho

Thu, 19 Feb 2026 06:48:08 -0400
Mizuho analyst Graig Suvannavejh raised the price target on Verastem (NASDAQ: VSTM) to $18.00 (from $15.00) while maintaining a Outperform rating.

Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026

Wed, 18 Feb 2026 07:30:00 -0400

BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its fourth quarter and full year 2025 financial results and business updates on Wednesday, March 4, 2026, at 4:30 pm ET.
To access the conference call, please dial (888) 596-4144 (U.S.) or (646) 968-2525 (international) and enter the passcode 7321921 at least 10 minutes prior to the event start time. A live audio webcast of the call, along with accompanying slides, will be available

Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026

Wed, 18 Feb 2026 07:30:00 -0400

BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its fourth quarter and full year 2025 financial results and business updates on Wednesday, March 4, 2026, at 4:30 pm ET.
To access the conference call, please dial (888) 596-4144 (U.S.) or (646) 968-2525 (international) and enter the passcode 7321921 at least 10 minutes prior to the event start time. A live audio webcast of the call, along with accompanying slides, will be available

Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026

Wed, 18 Feb 2026 07:30:00 -0400

BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its fourth quarter and full year 2025 financial results and business updates on Wednesday, March 4, 2026, at 4:30 pm ET.
To access the conference call, please dial (888) 596-4144 (U.S.) or (646) 968-2525 (international) and enter the passcode 7321921 at least 10 minutes prior to the event start time. A live audio webcast of the call, along with accompanying slides, will be available

Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026

Wed, 18 Feb 2026 07:30:00 -0400

BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its fourth quarter and full year 2025 financial results and business updates on Wednesday, March 4, 2026, at 4:30 pm ET.
To access the conference call, please dial (888) 596-4144 (U.S.) or (646) 968-2525 (international) and enter the passcode 7321921 at least 10 minutes prior to the event start time. A live audio webcast of the call, along with accompanying slides, will be available

Form SCHEDULE 13G Verastem, Inc. Filed by: ARMISTICE CAPITAL, LLC

Tue, 17 Feb 2026 21:43:00 -0400
si-local-file:///var/storage/secattach/20260217/26016305.html

Form SCHEDULE 13G Verastem, Inc. Filed by: ARMISTICE CAPITAL, LLC

Tue, 17 Feb 2026 21:43:00 -0400
si-local-file:///var/storage/secattach/20260217/26016305.html

Form SCHEDULE 13G/A Verastem, Inc. Filed by: Point72 Asset Management, L.P.

Tue, 17 Feb 2026 16:35:00 -0400
si-local-file:///var/storage/secattach/20260217/26014011.html